Integrated Filing — IndAS



General information about company

Scrip Code 533573
NSE Symbol APLLTD
MSEI Symbol NOTLISTED
ISIN INE901L01018
Name of company ALEMBIC PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 04-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 28-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 04-11-2026   11:30:00
End date and time of board meeting 04-11-2026   14:10:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public No
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. No
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 03-02-2025
Indicate Company website link for updated RPT policy of the Company https://alembicpharmaceuticals.com/policies-and-codes
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 2,39,165.00 4,25,972.00
Other income 2,442.00 3,846.00
Total income 2,41,607.00 4,29,818.00
2 Expenses
(a) Cost of materials consumed 59,964.00 1,11,694.00
(b) Purchases of stock-in-trade 13,424.00 25,416.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (3,026.00) (11,250.00)
(d) Employee benefit expense 45,420.00 87,066.00
(e) Finance costs 2,667.00 4,808.00
(f) Depreciation, depletion and amortisation expense 8,441.00 16,696.00
(f) Other Expenses
1 Other Expenses 61,236.00 1,16,316.00
Total other expenses 61,236.00 1,16,316.00
Total expenses 1,88,126.00 3,50,746.00
3 Total profit before exceptional items and tax 53,481.00 79,072.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 53,481.00 79,072.00
6 Tax expense
7 Current tax 9,600.00 13,934.00
8 Deferred tax 2,945.00 4,506.00
9 Total tax expenses 12,545.00 18,440.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 40,936.00 60,632.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 40,936.00 60,632.00
17 Other comprehensive income net of taxes (541.00) (431.00)
18 Total Comprehensive Income for the period 40,395.00 60,201.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 3,931.00 3,931.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 20.83 30.85
Diluted earnings (loss) per share from continuing operations 20.83 30.85
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 20.83 30.85
Diluted earnings (loss) per share from continuing and discontinued operations 20.83 30.85
24 Debt equity ratio 0.1900 0.1900
25 Debt service coverage ratio 21.0600 17.4500
26 Interest service coverage ratio 21.0600 17.4500
27 Disclosure of notes on financial results



Remarks

Debt equity ratio Number mentioned in times
Debt service coverage ratio Number mentioned in times
Interest service coverage ratio Number mentioned in times


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 2,89,300.00
Capital work-in-progress 54,284.00
Investment property
Goodwill 0.00
Other intangible assets 0.00
Intangible assets under development 5,147.00
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 27,679.00
Trade receivables, non-current
Loans, non-current 7,721.00
Other non-current financial assets
Total of other non-current financial assets
Total non-current financial assets 35,400.00
Deferred tax assets (net) 13,540.00
Other non-current assets
1 Other non-current assets 2,858.00
Total of other non-current assets 2,858.00
Total non-current assets 4,00,529.00
2 Current assets
Inventories 2,19,492.00
Current financial asset
Current investments 0.00
Trade receivables, current 2,03,298.00
Cash and cash equivalents 664.00
Bank balance other than cash and cash equivalents 727.00
Loans, current 6,554.00
Other current financial assets
Total of other current financial assets 1,368.00
Total current financial assets 2,12,611.00
Current tax assets (net) 3.00
Other current assets
1 Other current assets 32,804.00
Total of other current assets 32,804.00
Total current assets 4,64,910.00
3 Non-current assets classified as held for sale 3,000.00
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 8,68,439.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 3,931.00
Other equity 5,94,208.00
Total equity attributable to owners of parent 5,98,139.00
Non controlling interest
Total equity 5,98,139.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 1,777.00
Total of other non-current financial liabilities 1,777.00
Total non-current financial liabilities 1,777.00
Provisions, non-current 16,586.00
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 18,363.00
Current liabilities
Current financial liabilities
Borrowings, current 1,11,150.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 6,400.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 82,213.00
Total Trade payable 88,613.00
Other current financial liabilities
1 Other current financial liabilities 16,617.00
2 Lease Liabilities 1,983.00
Total of other current financial liabilities 18,600.00
Total current financial liabilities 2,18,363.00
Other current liabilities 9,879.00
1 Other current liabilities 9,879.00
Total of other current liabilities 9,879.00
Provisions, current 11,828.00
Current tax liabilities (Net) 11,867.00
Deferred government grants, Current
Total current liabilities 2,51,937.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 2,70,300.00
Total equity and liabilites 8,68,439.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit / (loss) (269.00) (318.00)
Total Amount of items that will not be reclassified to profit and loss (269.00) (318.00)
2 Income tax relating to items that will not be reclassified to profit or loss (68.00) (80.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit / (loss) (454.00) (258.00)
Total Amount of items that will be reclassified to profit and loss (454.00) (258.00)
4 Income tax relating to items that will be reclassified to profit or loss (114.00) (65.00)
5 Total Other comprehensive income (541.00) (431.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 79,072.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 4,808.00
Adjustments for decrease (increase) in inventories (14,676.00)
Adjustments for decrease (increase) in trade receivables, current (48,907.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (3,748.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 3.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 22,782.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (10,173.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 16,696.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (11,906.00)
Adjustments for provisions, non-current 13,667.00
Adjustments for other financial liabilities, current 12,232.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 1,200.00
Adjustments for dividend income 0.00
Adjustments for interest income 976.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (302.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (77.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 9.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (19,368.00)
Net cash flows from (used in) operations 59,704.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 6,378.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 53,326.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 237.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 1,186.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 5.00
Purchase of property, plant and equipment 16,877.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 4,811.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 601.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 1,518.00
Net cash flows from (used in) investing activities (20,987.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 3,799.00
Payments of lease liabilities 1,292.00
Dividends paid 23,588.00
Interest paid 5,178.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (85.00)
Net cash flows from (used in) financing activities (33,942.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (1,603.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (1,603.00)
Cash and cash equivalents cash flow statement at beginning of period 2,267.00
Cash and cash equivalents cash flow statement at end of period 664.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Loan 1,75,000.00 Consolidated Limit across all Subsidiaries 0.00 1,138.00 1,150.00 Loan 7.00 3 Years Unsecured Business Purpose Textual Information(1)
2 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Loan 1,75,000.00 Consolidated Limit across all Subsidiaries 0.00 4,742.00 4,792.00 Loan 7.700 3 Years Unsecured Business Purpose Textual Information(2)
3 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Loan 1,75,000.00 Consolidated Limit across all Subsidiaries 0.00 948.00 958.00 Loan 6.7900 3 Years Unsecured Business Purpose Textual Information(3)
4 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Interest received 1,75,000.00 Consolidated Limit across all Subsidiaries 438.00 608.00 990.00 Textual Information(4)
5 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Sale of goods or services 2,00,000.00 No remarks 32,932.00 14,323.00 9,670.00
6 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Investment 0.00 No remarks 0.00 3,031.00 3,031.00 Investment 0 NA Unsecured Business Purpose Textual Information(5)
7 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Loan 1,75,000.00 Consolidated Limit across all Subsidiaries 0.00 1,138.00 1,150.00 Loan 6.5700 3 Years Unsecured Business Purpose Textual Information(6)
8 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Loan 1,75,000.00 Consolidated Limit across all Subsidiaries 0.00 2,845.00 2,875.00 Loan 5.9900 3 Years Unsecured Business Purpose Textual Information(7)
9 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Any other transaction Reimbursement Paid 0.00 No remarks 39.00 0.00 0.00
10 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Loan 1,75,000.00 Consolidated Limit across all Subsidiaries 0.00 1,897.00 1,917.00 Loan 5.9500 3 Years Unsecured Business Purpose Textual Information(8)
11 Alembic Pharmaceuticals Ltd. Alembic Ltd. Promoter Any other transaction Service Received 4,956.00 No remarks 977.00 437.00 194.00
12 Alembic Pharmaceuticals Ltd. Alembic Ltd. Promoter Any other transaction Reimbursement Paid 826.00 No remarks 217.00 0.00 0.00
13 Alembic Pharmaceuticals Ltd. Alembic Ltd. Promoter Any other transaction Rent Paid 2,006.00 No remarks 715.00 0.00 0.00
14 Alembic Pharmaceuticals Ltd. Alembic Ltd. Promoter Sale of goods or services 236.00 No remarks 4.00 0.00 0.00
15 Alembic Pharmaceuticals Ltd. Alembic Ltd. Promoter Any other transaction Deposit Given 0.00 No remarks 0.00 397.00 397.00
16 Alembic Pharmaceuticals Ltd. Alembic Ltd. Promoter Purchase of goods or services 1,416.00 No remarks 572.00 0.00 0.00
17 Alembic Pharmaceuticals Ltd Alembic Pharma SPA Chile Wholly owned Subsidiary Investment 0.00 No remarks 0.00 240.00 240.00 Investment 0 NA Unsecured Business Purpose Textual Information(9)
18 Alembic Pharmaceuticals Ltd Alembic Pharma SPA Chile Wholly owned Subsidiary Loan 1,75,000.00 No remarks 0.00 1,897.00 0.00 Loan 7.00 3 Years Unsecured Business Purpose Textual Information(10)
19 Alembic Pharmaceuticals Ltd Alembic Pharma SPA Chile Wholly owned Subsidiary Sale of goods or services 50,000.00 No remarks 3,640.00 5,400.00 6,794.00
20 Alembic Pharmaceuticals Ltd Alembic Pharma SPA Chile Wholly owned Subsidiary Interest received 1,75,000.00 No remarks 28.00 0.00 0.00 Textual Information(11)
21 Alembic Pharmaceuticals Ltd Alembic Pharma SPA Chile Wholly owned Subsidiary Any other transaction Corporate Guarantee given 1,75,000.00 No remarks 0.00 10,005.00 10,110.00 Textual Information(12)
22 Alembic Pharmaceuticals Ltd Alembic Pharma SPA Chile Wholly owned Subsidiary Any other transaction Corporate Guarantee given 1,75,000.00 No remarks 0.00 9,483.00 9,583.00 Textual Information(13)
23 Alembic Pharmaceuticals Ltd Alembic Global Holding SA Wholly owned Subsidiary Any other transaction Purchase of Securities 0.00 No remarks 0.00 1,205.00 23.00 Investment 0 NA Unsecured Business Purpose Textual Information(14)
24 Alembic Pharmaceuticals Ltd. Bhailal Amin General Hospital � Promoter Group Purchase of goods or services 1,180.00 No remarks 257.00 62.00 80.00
25 Alembic Pharmaceuticals Ltd. Alembic City Ltd. Promoter Group Any other transaction Rent Paid 115.00 No remarks 69.00 0.00 0.00
26 Alembic Pharmaceuticals Ltd. Alembic City Ltd. Promoter Group Any other transaction Deposit Given 0.00 No remarks 12.00 32.00 44.00
27 Alembic Pharmaceuticals Ltd. Alembic City Ltd. Promoter Group Any other transaction Reimbursement Paid 0.00 No remarks 26.00 0.00 0.00
28 Alembic Pharmaceuticals Ltd. Alembic CSR Foundation Other Related Parties Any other transaction CSR Contribution 668.00 No remarks 668.00 0.00 0.00
29 Alembic Pharmaceuticals Ltd. ALEMBIC PHARMACEUTICALS SA de CV Fellow Subsidiary Loan 1,75,000.00 No remarks 0.00 190.00 192.00 Loan 6.6100 3 years Unsecured Business Purpose Textual Information(15)
30 Alembic Pharmaceuticals Ltd. ALEMBIC PHARMACEUTICALS SA de CV Fellow Subsidiary Interest received 1,75,000.00 No remarks 13.00 11.00 12.00 Textual Information(16)
31 Alembic Pharmaceuticals Ltd. ALEMBIC PHARMACEUTICALS SA de CV Fellow Subsidiary Investment 0.00 No remarks 0.00 3.00 3.00 Investment 0 NA Unsecured Business Purpose Textual Information(17)
32 Alembic Pharmaceuticals Ltd. ALEMBIC PHARMACEUTICALS SA de CV Fellow Subsidiary Loan 1,75,000.00 No remarks 237.00 0.00 240.00 Loan 6.8800 5 Years Unsecured Business Purpose Textual Information(18)
33 Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals Limited Provident Fund Other Related Parties Any other transaction Post Retirement benefits 7,406.00 No remarks 7,406.00 0.00 0.00
34 Alembic Pharmaceuticals Ltd. Shreno Ltd. Promoter Group Purchase of goods or services 236.00 No remarks 13.00 0.00 0.00
35 Alembic Pharmaceuticals Ltd. Shreno Ltd. Promoter Group Any other transaction Rent Paid 66.00 No remarks 33.00 0.00 0.00
36 Alembic Pharmaceuticals Ltd. Shreno Ltd. Promoter Group Any other transaction Deposit Given 0.00 No remarks 0.00 8.00 8.00
37 Alembic Pharmaceuticals Ltd Alembic Pharmaceuticals Inc. Wholly owned Subsidiary Any other transaction Corporate Guarantee given 1,75,000.00 No remarks 10,583.00 40,777.00 51,748.00 Textual Information(19)
38 Alembic Pharmaceuticals Ltd Alembic Pharmaceuticals Inc. Wholly owned Subsidiary Investment 0.00 No remarks 0.00 12,236.00 12,236.00 Investment 0 NA Unsecured Business Purpose Textual Information(20)
39 Alembic Pharmaceuticals Ltd Alembic Pharmaceuticals Inc. Wholly owned Subsidiary Sale of goods or services 5,00,000.00 No remarks 1,23,027.00 95,846.00 1,36,720.00
40 Alembic Pharmaceuticals Ltd Alembic Pharmaceuticals Inc. Wholly owned Subsidiary Any other transaction Reimbursement Paid 0.00 No remarks 2,580.00 0.00 0.00
41 Alembic Pharmaceuticals Ltd Alembic Pharmaceuticals Inc. Wholly owned Subsidiary Any other transaction Guarantee commission Received 0.00 No remarks 0.00 0.00 0.00
42 Alembic Pharmaceuticals Ltd. Shreno Publications Ltd. Promoter Group Purchase of goods or services 11,800.00 No remarks 3,626.00 507.00 620.00
43 Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals Europe Ltd. Step down Subsidiary Any other transaction Reimbursement Paid 1,137.00 No remarks 1,137.00 247.00 0.00
44 Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals Australia Pty Ltd. Step down Subsidiary Any other transaction Reimbursement Paid 236.00 No remarks 236.00 109.00 0.00
45 Alembic Pharmaceuticals Ltd. Paushak Ltd. Promoter Group Purchase of goods or services 1,180.00 No remarks 457.00 16.00 57.00
46 Alembic Pharmaceuticals Ltd. Paushak Ltd. Promoter Group Any other transaction Reimbursement Received 150.00 No remarks 22.00 0.00 0.00
47 Alembic Pharmaceuticals Ltd. Shreno Engineering Ltd. Promoter Group Purchase of fixed assets 2,891.00 No remarks 1,383.00 60.00 77.00
48 Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals Limited Gratuity Fund Other Related Parties Any other transaction Post Retirement benefits 2,050.00 No remarks 500.00 0.00 0.00
49 Alembic Pharmaceuticals Ltd. Laburnam Management Services Other Related Parties Purchase of goods or services 708.00 No remarks 48.00 20.00 34.00
50 Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals Scientific OfficeLLC Other Related Parties Investment 13.00 No remarks 0.00 13.00 13.00 Investment 0 NA Unsecured Business Purpose Textual Information(21)
51 Alembic Pharmaceuticals Ltd. Alembic LifeSciences Inc. Other Related Parties Purchase of goods or services 1,000.00 No remarks 285.00 351.00 96.00 Textual Information(22)
52 Alembic Pharmaceuticals Ltd. Rhizen Pharmaceuticals AG Associate of Subsidiary Any other transaction Reimbursement Paid 0.00 No remarks 0.00 99.00 101.00
53 Alembic Pharmaceuticals Ltd. Fenix Research Labs Private Limited Associate Investment 0.00 No remarks 0.00 300.00 300.00 Investment 0 NA Unsecured Business Purpose Textual Information(23)
54 Alembic Pharmaceuticals Ltd. Fenix Research Labs Private Limited Associate Purchase of goods or services 5,900.00 No remarks 26.00 1.00 2.00
55 Alembic Pharmaceuticals Ltd. Chirayu Ramanbhai Amin Key Managerial Personnel Remuneration 1,050.00 No remarks 493.00 500.00 0.00 Textual Information(24)
56 Alembic Pharmaceuticals Ltd. Pranav Chirayu Amin Key Managerial Personnel Remuneration 1,600.00 No remarks 743.00 500.00 0.00 Textual Information(25)
57 Alembic Pharmaceuticals Ltd. Shaunak Chirayu Amin Key Managerial Personnel Remuneration 1,600.00 No remarks 743.00 500.00 0.00 Textual Information(26)
58 Alembic Pharmaceuticals Ltd. Alembic Lifesciences Philippines Inc � Subsidiary Investment 187.00 No remarks 187.00 0.00 187.00 Investment 0 NA Unsecured Business Purpose Textual Information(27)
59 Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals (Thailand) Co. Ltd. Subsidiary Investment 22.00 No remarks 22.00 0.00 22.00 Investment 0 NA Unsecured Business Purpose Textual Information(28)
60 Alembic Pharmaceuticals Ltd. Alembic Pharmaceuticals Limited GmbH (Germany) � Subsidiary Investment 28.00 No remarks 28.00 0.00 28.00 Investment 0 NA Unsecured Business Purpose Textual Information(29)
61 Alembic Global Holding SA Rhizen Pharmaceuticals AG Associate Investment 0.00 No remarks 0.00 1,701.00 1,701.00 Investment 0 NA Unsecured Business Purpose Textual Information(30)
62 Alembic Global Holding SA TicTwo Therapeutics Inc. Subsidiary Loan 0.00 No remarks 0.00 6,875.00 6,948.00 Loan 9.00 3-5 Years Unsecured Business Purpose Textual Information(31)
63 Alembic Global Holding SA TicTwo Therapeutics Inc. Subsidiary Investment 0.00 No remarks 0.00 1.00 1.00 Investment 0 NA Unsecured Business Purpose Textual Information(32)
64 Alembic Global Holding SA TicTwo Therapeutics Inc. Subsidiary Interest received 0.00 No remarks 470.00 1,065.00 1,546.00 Textual Information(33)
65 Alembic Global Holding SA Alembic Lifescience INC. Subsidiary Loan 0.00 No remarks 0.00 343.00 16.00 Loan 6.3200 3 years Unsecured Business Purpose Textual Information(34)
66 Alembic Global Holding SA Alembic Lifescience INC. Subsidiary Interest received 0.00 No remarks 16.00 0.00 1.00 Textual Information(35)
67 Alembic Global Holding SA TicTwo Therapeutics Inc. Subsidiary Loan 0.00 No remarks 0.00 2,845.00 2,875.00 Loan 9.00 3-5 Years Unsecured Business Purpose Textual Information(36)
68 Alembic Global Holding SA Alembic Lifescience INC. Subsidiary Investment 0.00 No remarks 0.00 0.00 0.00 Investment 0 NA Unsecured Business Purpose Textual Information(37)
69 Alembic Global Holding SA 17989377 Canada Inc. Joint Venture Company Investment No remarks 958.00 0.00 958.00 Investment 0 NA Unsecured Business Purpose Textual Information(38)
70 Alembic Global Holding SA Alembic Global Holding Europe Wholly owned Subsidiary Purchase of goods or services 0.00 No remarks 0.00 33.00 0.00 Textual Information(39)
71 Alembic Global Holding SA Alembic Pharmaceuticals Canada Limited Wholly owned Subsidiary Any other transaction Reimbursement Paid 0.00 Consolidated Limit across all Subsidiaries 0.00 6.00 98.00 Textual Information(40)
72 Alembic Global Holding SA TicTwo Therapeutics Inc. Subsidiary Loan 0.00 No remarks 2,396.00 0.00 2,396.00 Loan 9.00 3-5 Years Unsecured Business Purpose Textual Information(41)
73 Alembic Global Holding SA Alembic Lifescience INC Subsidiary Loan 0.00 No remarks 264.00 0.00 95.00 Loan 6.3200 3 years Unsecured Business Purpose Textual Information(42)
74 Alembic Global Holding DMCC Alembic Pharmaceuticals Canada Limited Wholly owned Subsidiary Investment No remarks 0.00 0.00 0.00 Investment 0 NA Unsecured Business Purpose Textual Information(43)
75 Alembic Global Holding SA Alembic Pharmaceuticals Canada Limited Wholly owned Subsidiary Any other transaction Reimbursement Paid 0.00 No remarks 92.00 0.00 92.00 Textual Information(44)
76 Alembic Global Holding SA ALEMBIC PHARMACEUTICALS SA de CV Fellow Subsidiary Investment 0.00 No remarks 0.00 0.00 0.00 Investment 0 NA Unsecured Business Purpose Textual Information(45)
77 Alembic Global Holding SA 17989377 Canada Inc. Joint Venture Company Investment 0.00 No remarks 0.00 0.00 0.00 Investment 0 NA Unsecured Business Purpose Textual Information(46)
Total value of transaction during the reporting period 1,98,618.00



Text Block

Textual Information(1) Amount Change due to Exchange rate difference
Textual Information(2) Amount Change due to Exchange rate difference
Textual Information(3) Amount Change due to Exchange rate difference
Textual Information(4) On account of Interest received and Amount adjusted due to Exchange rate difference
Textual Information(5) Investment in Equity
Textual Information(6) Amount adjusted due to Exchange rate difference
Textual Information(7) Amount adjusted due to Exchange rate difference
Textual Information(8) Amount adjusted due to Exchange rate difference
Textual Information(9) Investment in Equity
Textual Information(10) Repayment of Loan
Textual Information(11) On account of Interest received
Textual Information(12) Amount Change due to Exchange rate difference
Textual Information(13) Amount Change due to Exchange rate difference
Textual Information(14) Since Alembic Global Holding SA is Offshore Entities and do not have PAN, we have mentioned ZZZZZ9999Z as PAN of Alembic Global Holding SA.
Textual Information(15) Amount Change due to Exchange rate difference
Textual Information(16) Amount adjusted due to Exchange rate difference
Textual Information(17) Investment in Equity
Textual Information(18) Amount Change due to Exchange rate difference
Textual Information(19) Amount Change due to Exchange rate difference
Textual Information(20) Equity Investment
Textual Information(21) Since Alembic Scientific Office LLC is Offshore Entities and do not have PAN, we have mentioned ZZZZZ9999Z as PAN of Alembic Scientific Office LLC.
Textual Information(22) Since Alembic Lifescience INC is Offshore Entities and do not have PAN, we have mentioned ZZZZZ9999Z as PAN of Alembic Lifescience INC.
Textual Information(23) Amount Change due to Exchange rate difference,Investment in Equity
Textual Information(24) The amount of the transaction of remuneration paid is mentioned on actual basis excluding the amount of commission paid for the previous year which was disclosed in the Diclosure filed for the Half year ended 31.03.2026.
Textual Information(25) The amount of the transaction of remuneration paid is mentioned on actual basis excluding the amount of commission paid for the previous year which was disclosed in the Diclosure filed for the Half year ended 31.03.2026.
Textual Information(26) The amount of the transaction of remuneration paid is mentioned on actual basis excluding the amount of commission paid for the previous year which was disclosed in the Diclosure filed for the Half year ended 31.03.2026.
Textual Information(27) Investment in Equity
Textual Information(28) Investment in Equity
Textual Information(29) Investment in Equity
Textual Information(30) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Rhizen Pharmaceuticals AG. Amount Change due to Exchange Difference. Investment in Equity
Textual Information(31) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of TicTwo Therapeutics Inc. Amount Change due to Exchange Difference
Textual Information(32) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of TicTwo Therapeutics Inc. Investment in Equity.
Textual Information(33) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of TicTwo Therapeutics Inc. Amount Change due to Exchange rate difference.
Textual Information(34) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Lifescience INC. Amount Change due to Exchange Difference
Textual Information(35) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Lifescience INC. Amount Change due to Exchange Difference
Textual Information(36) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of TicTwo Therapeutics Inc.
Textual Information(37) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Lifescience INC.100 USD Invested
Textual Information(38) Investment in preference shares. Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of 17989377 Canada Inc.
Textual Information(39) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Global Holding Europe.
Textual Information(40) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Pharmaceuticals Canada Limited.
Textual Information(41) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of TicTwo Therapeutics Inc.
Textual Information(42) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Lifescience INC.
Textual Information(43) Investment in Equity, 165.31 AED Invested. Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Pharmaceuticals Canada Limited.
Textual Information(44) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of Alembic Pharmaceuticals Canada Limited.
Textual Information(45) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of ALEMBIC PHARMACEUTICALS SA de CV. Amount Change due to Exchange Difference. Investment in Equity 33.24 USD Invested
Textual Information(46) Since both the Entities are Offshore Entities and do not have PAN, we have mentioned the PAN of Alembic Pharmaceuticals Limited in Alembic Global Holdings SA (AGHSA), being the Holding Company of AGHSA and ZZZZZ9999Z as PAN of 17989377 Canada Inc. Investment in Equity 45 USD Invested